News

Despite improvements, results from the study of SLS-005 (IV trehalose), a low molecular weight disaccharide, did not meet statistical significance.

New and renewed approaches to improve chances of success in developing non-addictive drugs for chronic pain.

Opdivo plus Yervoy was found to produce a statistically significant and clinically meaningful overall survival improvement compared with sorafenib or lenvatinib in patients with advanced hepatocellular carcinoma.

Results of cross-sectional study of 50 discharge summaries suggest a large language model can be used to increase their understandability.

Analysis of trial results show Imfinzi and Lynparza displayed a strong clinical benefit and more than doubled median duration of response vs. chemotherapy.

Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.

Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients based on results from the pivotal Phase III KarMMa-3 study.

In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.

Keytruda plus chemoradiotherapy found to significantly improve overall survival in patients newly diagnosed with high-risk locally advanced cervical cancer.

Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.

THARROS trial investigators seek to provide first-of-its-kind evidence supporting a strategy of comprehensive cardiopulmonary risk reduction with a triple therapy in patients with chronic obstructive pulmonary disease.

Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.

Although there are much larger problems in clinical research, storing obsolete study records is a totally unnecessary cost.

Clinical trials planned for the fourth quarter of 2024 will evaluate a new multi-valent vaccine to protect against multiple types of human papillomavirus, and to analyze the efficacy and safety of a single-dose of Gardasil 9.

Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.

Transparent and detailed communication throughout the research process is key for effectively recruiting and retaining patients for clinical trials.

Industry leaders discuss how technology can help companies adapt to the regulatory changes and accomplish their DE&I goals.

Adcetris (brentuximab vedotin) plus lenalidomide and rituximab produced statistically significant and clinically meaningful improvements in overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

Exploring a human-centered, holistic approach for equitable trial outcomes.

The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, speak on what they think the future looks like when it comes to streamlining and improving the clinical trial imaging landscape.

Exploring ways to boost the adoption of eCOA provider-specific libraries—an often-frustrating migration process, but one with significant payoffs in simplified workflows and reduced timelines.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

Leveraging an essential, new set of behaviorally informed best practices to break free from the constraints of the Iron Triangle of Clinical Trial Complexity.

Investigational, once-weekly combination shows promise as long-acting oral treatment option for those virologically suppressed with HIV.

Blenrep (belantamab mafodotin) combined with pomalidomide plus dexamethasone showed favorable progression-free survival compared with standard of care in the second-line and later treatment of relapsed or refractory multiple myeloma.

The six steps to designing a successful diversity action plan for a clinical trial protocol.